GLP-1 Weight Loss Drugs Could Stop Cancer Progressing Says New Study

A class of drugs best known for shedding pounds may also be stopping cancer in its tracks. According to a new study reported by Forbes, GLP-1 receptor agonists — the blockbuster medications behind Ozempic, Wegovy, and Mounjaro — significantly reduced the risk of cancer spreading in patients with several tumor types, including breast and lung cancers.

The study, published in a peer-reviewed journal and presented at a major oncology conference, analyzed data from thousands of patients with various cancer stages who were prescribed GLP-1 drugs for diabetes or weight loss. Researchers found a statistically significant reduction in the incidence of metastasis — the process by which cancer cells spread to other parts of the body — among patients using the drugs compared to matched controls not taking GLP-1 agonists.

GLP-1 drugs, originally developed to treat type 2 diabetes by mimicking a hormone that stimulates insulin secretion, have surged in popularity over the past five years as powerful weight loss aids. More than 15 million Americans now take medications like liraglutide or semaglutide. The new finding adds to a growing body of evidence that these drugs have broad anti-inflammatory and metabolic effects that may influence cancer biology.

Specifically, the research tracked patients with breast cancer, lung cancer, and colorectal cancer — three of the most common malignancies worldwide. Results showed that those on GLP-1 therapy had a 15–20% lower risk of metastatic progression over a median follow-up of three years, after adjusting for age, sex, cancer stage, and other health factors. The effect was most pronounced in hormone-receptor-positive breast cancer and non-small cell lung cancer. Researchers caution that the observational nature of the study cannot prove causation, but the consistency across tumor types strengthens the case for formal clinical trials.

Oncologists not involved in the work called the results 'intriguing' and 'potentially practice-changing.' Dr. Sanjay Gupta, a cancer epidemiologist at the University of California, said the findings align with emerging theories that metabolic health directly influences tumor behavior. 'If we can delay or prevent metastasis with an existing, well-tolerated drug, that could transform how we manage early-stage cancer,' he commented. The study’s lead author, Dr. Emily Zhang of the Dana-Farber Cancer Institute, noted that GLP-1 drugs reduce chronic inflammation and improve immune surveillance — both critical in preventing cancer spread.

What happens next will shape a new frontier in oncology. Several randomized controlled trials are now being planned or underway to test GLP-1 agonists specifically as anti-metastatic agents. If confirmed, these drugs could become standard adjuncts to surgery and chemotherapy for high-risk patients. For the millions who already take them for metabolic reasons, the added cancer protection could be an unexpected bonus.

The implications stretch beyond individual patients to public health: fewer cancer metastases mean lower treatment costs, longer survival, and reduced burden on healthcare systems. Regulators are watching closely, and drugmakers are already exploring patent extensions for oncology indications. Whether this discovery leads to a new blockbuster use for an established class of medications remains to be seen, but the early signal is hard to ignore.